Biovica Acquires cSens AB
Complete the form below to unlock access to ALL audio articles.
Biovica has acquired cSens AB for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness. The cSens technology complements Biovica’s current TK assay DiviTum™, which is currently included in clinical studies with leading cancer institute’s throughout the world.
The clinical programs document DiviTum™ as a tool for better evaluation of therapy efficacy in patients with advanced breast cancer, treated with endocrine therapies and CDK-inhibitors in estrogen receptor positive tumors. Early evaluation of efficacy contribute to optimal treatment for patients and cost effectiveness in the healthcare system.
In addition to the ability to measure TK clinically, the cSens diagnostic platform creates opportunities to expand pre-clinical measurements in cancer cell cultures and animal models. The platform can also be used to develop new biomarker assays and tests for other forms of cancer and novel drugs.
“We look forward to become a part of Biovica and to access the network of world leading oncologists and global pharmaceutical companies that Biovica work with. This creates a great opportunity for us to commercialize our technology and it will be exciting to follow the development henceforth!” says Leif Glantz, chairman of the board and CEO of cSens.
“The technology complements Biovica well and creates new opportunities for us to provide a faster and more automated platform. Furthermore, we create new opportunities to face new diagnostic needs with the platform and with the expertise of the cSens staff.” says Anders Rylander, CEO of Biovica.
